Lv2
194 积分 2022-01-04 加入
Expanding the Chemistry of Dihaloacetamides as Tunable Electrophiles for Reversible Covalent Targeting of Cysteines
1个月前
已完结
Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma
1个月前
已完结
The First Class of Small Molecules Potently Disrupting the YAP‐TEAD Interaction by Direct Competition
1个月前
已完结
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial
1个月前
已完结
OICR-41103 as a chemical probe for the DCAF1 WD40 domain
1个月前
已关闭
Natural product sennoside B disrupts liquid-liquid phase separation of SARS-CoV-2 nucleocapsid protein by inhibiting its RNA-binding activity
1个月前
已完结
Proton Craniospinal Irradiation for Patients With Leptomeningeal Metastasis
2个月前
已完结
Leptomeningeal Metastasis from Non–Small Cell Lung Cancer and Current Landscape of Treatments
2个月前
已完结
Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties
3个月前
已完结
Identification of a Novel, Potent, and Orally Bioavailable Guanidine-Based SHP2 Allosteric Inhibitor from Virtual Screening and Rational Structural Optimization for the Treatment of KRAS Mutant Cancers
4个月前
已完结
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
8个月前
已采纳
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
8个月前
已采纳
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
8个月前
已采纳
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
8个月前
已采纳
Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC
8个月前
已采纳
Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC
8个月前
已采纳
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
8个月前
已采纳
皖公网安备34019202002308
